Gennex Laboratories Ltd
Incorporated in 1995, Gennex Laboratories Ltd manufactures Bulk Drugs and Intermediaries[1]
- Market Cap ₹ 270 Cr.
- Current Price ₹ 11.9
- High / Low ₹ 29.0 / 11.2
- Stock P/E 16.4
- Book Value ₹ 8.21
- Dividend Yield 0.00 %
- ROCE 12.5 %
- ROE 9.09 %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 55.6% CAGR over last 5 years
- Debtor days have improved from 55.0 to 37.5 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 23.6%
- Company has a low return on equity of 9.25% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|
42 | 44 | 56 | 56 | 60 | 61 | 66 | 87 | 138 | 148 | |
37 | 42 | 52 | 52 | 53 | 56 | 61 | 70 | 121 | 126 | |
Operating Profit | 5 | 2 | 4 | 3 | 7 | 5 | 5 | 17 | 17 | 22 |
OPM % | 11% | 5% | 7% | 6% | 11% | 9% | 7% | 20% | 12% | 15% |
0 | 1 | 1 | 1 | 0 | 1 | 4 | 5 | 10 | 6 | |
Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 3 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 |
Profit before tax | 3 | 1 | 3 | 3 | 5 | 5 | 6 | 16 | 21 | 22 |
Tax % | 13% | 42% | 26% | 27% | 20% | 23% | 23% | 20% | 15% | |
3 | 1 | 2 | 2 | 4 | 4 | 5 | 13 | 18 | 19 | |
EPS in Rs | 0.14 | 0.04 | 0.12 | 0.10 | 0.21 | 0.21 | 0.28 | 0.58 | 0.71 | 0.71 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 20% |
3 Years: | 31% |
TTM: | 43% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 56% |
3 Years: | 61% |
TTM: | 13% |
Stock Price CAGR | |
---|---|
10 Years: | 16% |
5 Years: | 23% |
3 Years: | 18% |
1 Year: | -35% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 9% |
3 Years: | 9% |
Last Year: | 9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 18 | 23 | 23 |
Reserves | 18 | 19 | 21 | 23 | 27 | 31 | 62 | 148 | 164 |
4 | 2 | 5 | 5 | 7 | 10 | 1 | 6 | 27 | |
14 | 16 | 13 | 16 | 12 | 14 | 51 | 54 | 42 | |
Total Liabilities | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 230 | 256 |
16 | 16 | 16 | 15 | 14 | 14 | 74 | 56 | 60 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 |
Investments | 7 | 7 | 7 | 7 | 7 | 7 | 0 | 0 | 0 |
26 | 28 | 29 | 35 | 38 | 48 | 59 | 172 | 191 | |
Total Assets | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 230 | 256 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
-0 | 3 | 2 | -2 | -1 | 12 | 24 | -47 | -11 | |
-1 | -1 | -1 | -0 | -0 | -2 | -38 | 19 | 1 | |
1 | -2 | 1 | -0 | 2 | -2 | 21 | 74 | 5 | |
Net Cash Flow | -0 | 0 | 2 | -2 | 0 | 8 | 6 | 46 | -5 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 90 | 87 | 68 | 41 | 55 | 67 | 52 | 75 | 37 |
Inventory Days | 43 | 31 | 57 | 78 | 50 | 72 | 139 | 184 | 135 |
Days Payable | 139 | 161 | 88 | 86 | 59 | 72 | 63 | 111 | 49 |
Cash Conversion Cycle | -7 | -43 | 38 | 34 | 46 | 67 | 129 | 148 | 123 |
Working Capital Days | 74 | 75 | 56 | 87 | 108 | 87 | 23 | 255 | 214 |
ROCE % | 6% | 11% | 8% | 14% | 12% | 11% | 14% | 12% |
Documents
Announcements
-
Board Meeting Intimation for Fixing Date, Time And Venue Of 40Th AGM Of The Company
26 Aug - Board meeting on Sep 04, 2025 at 4:00 PM to decide 40th AGM and appoint scrutinizer.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
18 Aug - Newspaper publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter ended June 30, 2025 announced by the Board in its meeting held on …
-
Unaudited Financial Results For The Quarter Ended June 30 2025
14 Aug - Gennex reports Q1 FY26 unaudited standalone and consolidated financial results with net profit Rs.414.95L standalone.
-
Board Meeting Outcome for Outcome Of The Board Meeting Of Gennex Laboratories Limited Held On August 14, 2025 For Unaudited Financial Results Of First Quarter Ended June 30, 2025
14 Aug - Gennex Labs Q1 FY26 unaudited results: standalone profit Rs.414.95L, consolidated profit Rs.501.64L, approved by board.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 Aug - Newspaper publication regarding Meeting of Board of the Company scheduled to be held on Thursday, August 14, 2025 for adoption of Unaudited (Standalone and Consolidated) …
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
GLL is an ISO 9001:2008, TUV, ISO 14001 and OSHAS 18000 certified vertically integrated Active Pharmaceutical Ingredient manufacturer & exporter of Bulk Drugs, Intermediates and Biotech Products in the form of Expectorants,
Muscle Relaxants, Analgesic and Anti Fungal, etc.